Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aram F Hezel

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancerBrinda Alagesan, Gianmarco Contino, Alex R Guimaraes, et al.
Gastroenterology|February 12, 2009
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinomaRuben Plentz, Ji-Sun Park, Andrew D Rhim, et al.
Clinical Colorectal Cancer|December 14, 2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 10, 2016
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal AdenocarcinomaVikram Deshpande, Ioannis T Konstantinidis, Carlos Fernandez-Del Castillo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouseNabeel Bardeesy, Andrew J Aguirre, Gerald C Chu, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapyBrian M Alexander, Carlos Fernandez-Del Castillo, David P Ryan, et al.
Carcinogenesis|February 20, 2008
Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancerSamanthi A Perera, Richard S Maser, Huili Xia, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
Gut|September 20, 2018
ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreasWenjia Wang, Scott C Friedland, Bing Guo, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancerBrinda Alagesan, Gianmarco Contino, Alex R Guimaraes, et al.
Gastroenterology|February 12, 2009
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinomaRuben Plentz, Ji-Sun Park, Andrew D Rhim, et al.
Clinical Colorectal Cancer|December 14, 2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713Cynthia Gail Leichman, Shannon L McDonough, Stephen R Smalley, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|March 10, 2016
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal AdenocarcinomaVikram Deshpande, Ioannis T Konstantinidis, Carlos Fernandez-Del Castillo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouseNabeel Bardeesy, Andrew J Aguirre, Gerald C Chu, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapyBrian M Alexander, Carlos Fernandez-Del Castillo, David P Ryan, et al.
Carcinogenesis|February 20, 2008
Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancerSamanthi A Perera, Richard S Maser, Huili Xia, et al.
The Oncologist|January 3, 2012
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximabRaymond C Wadlow, Aram F Hezel, Thomas A Abrams, et al.
Gut|September 20, 2018
ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreasWenjia Wang, Scott C Friedland, Bing Guo, et al.
Pageof 7